Skip to main content

Gut microbiome/metabolome predicts response to immune checkpoint blockers (ICB) in patients with recurrent metastatic head and neck squamous cell cancer (RM HNSCC).

Publication ,  Conference
Bari, S; Jain, S; Yadav, H; Liu, M; Hodge, E; Kirtane, K; Chung, CH; Conejo-Garcia, J; Muzaffar, J
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2022

Volume

40

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bari, S., Jain, S., Yadav, H., Liu, M., Hodge, E., Kirtane, K., … Muzaffar, J. (2022). Gut microbiome/metabolome predicts response to immune checkpoint blockers (ICB) in patients with recurrent metastatic head and neck squamous cell cancer (RM HNSCC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Bari, Shahla, Shalini Jain, Hariom Yadav, Min Liu, Eli Hodge, Kedar Kirtane, Christine H. Chung, Jose Conejo-Garcia, and Jameel Muzaffar. “Gut microbiome/metabolome predicts response to immune checkpoint blockers (ICB) in patients with recurrent metastatic head and neck squamous cell cancer (RM HNSCC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Bari S, Jain S, Yadav H, Liu M, Hodge E, Kirtane K, Chung CH, Conejo-Garcia J, Muzaffar J. Gut microbiome/metabolome predicts response to immune checkpoint blockers (ICB) in patients with recurrent metastatic head and neck squamous cell cancer (RM HNSCC). JOURNAL OF CLINICAL ONCOLOGY. 2022.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2022

Volume

40

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences